BeOne Medicines

Tevimbra (tislelizumab) is a PD-1 checkpoint inhibitor from BeOne Medicines for esophageal squamous cell carcinoma, gastric and gastroesophageal junction adenocarcinoma, and non-small cell lung cancer. By releasing the PD-1 brake on T cells, it restores immune attack on tumours, alone or with chemotherapy.

T cells are built to destroy abnormal cells, but many cancers protect themselves by displaying ligands PD-L1 and PD-L2 that bind the PD-1 off-switch o

Brukinsa (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor from BeOne Medicines for several mature B-cell cancers, including mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma, and follicular lymphoma in combination with obinutuzumab.

Zanubrutinib is a capsule that blocks Bruton's tyrosine kinase (BTK), an enzyme B-cell cancers need to receive growth and survival signals. By switchi